• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Celyad to present at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day

March 15, 2016 By Celyad

Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ:
CYAD), a leader in the discovery and development of engineered cell therapies, with clinical
programs in cardiovascular disease and immuno-oncology, today announced that Steve
Buckanavage, Vice-President Global Marketing will be presenting for the company at the
Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day in New
York City on Tuesday, March 22, 2016 at TIME EST.
Steve Buckanavage: “We are excited to participate in the conference and provide an
update on Celyad’s activities and key milestones in immune-oncology and cardiology for

  1. We believe our unique immuno-oncology approach in engineered T-Cells, with our
    natural killer receptor program called NKR T-Cells, will generate interest on the part of peers
    and investors.“
    This event is organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with
    Piper Jaffray. A live-streaming webcast of all panels and company presentations will be
    available at: http://www.arminvestorday.com/webcast and will be published on the event’s
    website shortly after the conference.
Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use